ACUR (Acura Pharmaceuticals) Payments of Debt: $-0.02 Mil (TTM As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACUR Acura Pharmaceuticals Inc ACUR
16 GF Score
Price $0.00
View Full Analysis

What is Acura Pharmaceuticals Payments of Debt?

Acura Pharmaceuticals ACUR 16 Payments of Debt is $-0.02 Mil as of Dec. 2021. GuruFocus rates ACUR with a GF Score™ of 16/100.

Acura Pharmaceuticals's Payments of Debt for the three months ended in Dec. 2021 was $-0.02 Mil.

Acura Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.02 Mil.

Acura Pharmaceuticals Payments of Debt Related Terms

Acura Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Payments of Debt Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.76 -2.57 0.00 0.00 -0.02

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.02
ACUR
16GF Score
Acura Pharmaceuticals Inc ACUR
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.02 Mil mean?
Acura Pharmaceuticals (ACUR) has a Payments of Debt of $-0.02 Mil as of Dec. 2021. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Payments of Debt too high?
Acura Pharmaceuticals' current Payments of Debt is $-0.02 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Payments of Debt compare to VFRM and THCT?
Acura Pharmaceuticals' Payments of Debt of $-0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Payments of Debt is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (ACUR) has a current Payments of Debt of $-0.02 Mil. The current Payments of Debt is $-0.02 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Acura Pharmaceuticals (ACUR), the current Payments of Debt is $-0.02 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for ACUR

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price